Chapter 3 The Australian Nuclear Science and Technology Organisation
(ANSTO) Nuclear Medicine Project
3.1
The Australian Nuclear Science and Technology Organisation (ANSTO) produces
and sells nuclear medicine, including Molybdenum-99 (Mo-99).
3.2
The project has two parts:
- a facility to process
Mo-99 into a form suitable for use by over 200 hospitals in Australia and New
Zealand
- a facility to produce
a synthetic rock material (Synroc) from the waste by-product of nuclear
medicine production.
3.3
The purpose of the project is to provide a secure supply of Mo-99 and to
treat waste for safe disposal.
3.4
The cost of the project is $168.8 million.
3.5
The project was referred to the Committee on 29 November 2012.
Conduct of the inquiry
3.6
Following referral to the Committee, the inquiry was advertised on the
Committee’s website, by media release and in the St George and Sutherland
Shire Leader newspaper.
3.7
The Committee received one submission and two supplementary submissions
from ANSTO. The Committee also received submissions from two other
organisations. The list of submissions can be found at Appendix A.
3.8
The Committee received a private briefing and conducted a site
inspection, a public hearing and an in-camera hearing on 1 February 2013 in
Sydney.
3.9
A transcript of the public hearing and the submissions to the inquiry
are available on the Committee’s website.[1]
Need for the works
3.10
ANSTO is currently dependent on its existing Mo-99 plant and imports of
nuclear medicine to ensure a reliable supply to Australia. This plant is ageing
and will reach the end of its useful life in 2017.
3.11
The existing Mo-99 facility was retro-fitted with the existing suite of
radiation shielding enclosures or ‘hot cells’ in 2006. This plant was designed
and commissioned as a demonstration plant with a life of 10 years. It was
always anticipated that this plant would be superseded within its design life.
3.12
The purpose of the Synroc waste treatment facility will be to treat the
waste which is a necessary by-product of nuclear medicine production. Synroc
technology is an Australian innovation which immobilises nuclear waste into a
synthetic rock which is safe for long-term storage. The Synroc plant will also
be used to treat legacy waste from over 50 years of Australian nuclear medicine
production into a form suitable for ultimate disposal.
3.13
The plant could also create excellent spin-off opportunities for
Australia. Australia will not store other countries’ waste. However, the Synroc
plant will become an operating demonstration facility to showcase how Synroc
technology could be exported with significant commercialisation potential.[2]
3.14
ANSTO determined that the existing Mo-99 facility could not be
refurbished and considered other options for processing Mo-99. In its
submission, ANSTO explained why it proposes to construct a new facility. ANSTO
also assessed various options for disposing of nuclear waste and provided
reasons for proposing the Synroc facility.[3]
3.15
The Committee is satisfied that there is a need for the works.
Scope of the works
3.16
The Mo-99 facility will contain:
- a production area
with radiation shielding enclosures for the handling, process and maintenance
of the facility
- tanks for the interim
storage of production liquid wastes
- a treatment system
for production off-gases
- laboratories for
analysing starting materials and finished product
- a product dispatch area
- staff amenities
- reticulated building
services, including water, waste water, ventilation, electrical, lighting,
security, fire detection, alarms and public address.[4]
3.17
The Synroc plant will contain three areas:
- the white area which
contains offices, meeting rooms, and hot cell operations rooms
- the blue area which
contains space for the support of the hot cell equipment
- the red area which
contains the hot cells for the purpose of processing the waste into a synthetic
rock material.[5]
3.18
The Synroc project contains an approved test and evaluation plant, which
will be essential to demonstrate the technology to the regulator whilst seeking
regulatory approvals. The test and evaluation plant will also serve as a useful
training tool and marketing device.[6]
3.19
The Committee finds that the proposed scope of works is suitable to meet
the need.
Cost of the works
3.20
The project cost is $168.8 million. The Committee received a
confidential supplementary submission detailing the project costs and held an
in-camera hearing with ANSTO on these costs.
3.21
The Committee is satisfied that the costings for the project provided to
it have been adequately assessed by the proponent agency.
Project issues
Community consultation and waste management
3.22
The Sutherland Shire Council, where the Lucas Heights site is located, made
a submission to the inquiry. This submission raised issues including the lack
of a national nuclear waste repository, a lack of information on the project, and
the scale and safety of the facilities.[7]
3.23
ANSTO is a large employer within the Sutherland Shire and many of its
employees live in the Shire. ANSTO stated that it has ongoing consultation with
the Council and the local community.[8]
3.24
The Council expressed concern that the Synroc plant would process
nuclear waste from other countries and that waste would be stored on the
grounds of ANSTO’s Lucas Heights site.[9]
3.25
ANSTO agreed that the key public concern was waste management. The Chief
Executive Officer of ANSTO affirmed that:
We have no intention of processing other countries' waste
locally.[10]
3.26
Regarding waste storage on site, ANSTO stated that it was also concerned
that waste would not be removed from Lucas Heights:
… our [A]ct does not permit us to become the long-term waste
repository and store. So the [P]arliament has already anticipated that and it
is a very strong position we can take. I am certain the regulator—because they
are also required to reflect international best practice, which I think is the
term in the [A]ct—would never allow this to become a permanent repository and
store, because it would fly in the face of what everybody else has agreed at
the International Atomic Energy Agency.[11]
3.27
Furthermore, ANSTO stated that it advocates against the long-term
storage of nuclear waste at its Lucas Heights site.[12]
We have regularly engaged in Senate estimates and other
settings, explaining the importance of Australia as a country that meets
international best practice, which is to have a national waste repository and
store. Typically, these are located in remote sites that are geologically and
otherwise stable for these storage purposes. We have assisted the department
responsible for that with our expertise in interim waste management, as we do
on the site, to assist them in developing the process by which it is happening.[13]
3.28
ANSTO affirmed that it is encouraged by and supportive of the
development of a national waste repository and store. ANSTO indicated that it
is responsible for maintaining the interim storage facilities and building public
confidence in nuclear waste management.[14]
3.29
The lack of information regarding the facilities is due to the fact that
the detailed design stages have not yet commenced. This is explained further in
the Costs section below. However, ANSTO stated that it is happy to share
detailed design information with the Council when it is developed.[15]
This will provide the Council with further detail on the size and scale of the
facilities.
3.30
Further, ANSTO indicated that the size and scale of nuclear facilities
does not affect safety:
… scale and safety are not correlated in my view. It is
always safe, and scale is simply the scale you require to deliver the result.[16]
3.31
ANSTO also reaffirmed that it is not able to operate any nuclear
facilities without the approval of the independent regulator, the Australian Radiation
Protection and Nuclear Safety Agency (ARPANSA).
[ARPANSA’s] statute and mandate goes to the issue of public
accountability for safety and health for the public and the broader environment
itself. So the public can be reassured that there are sufficient independent
processes to look to public safety, to look to the safety of operations and the
work and safety environment in which we operate. We would not be permitted to
proceed if there was any risk to the public in this regard.[17]
3.32
ANSTO noted that two reactors in Canada were constructed but were prohibited
from being operated by the Canadian regulator, demonstrating the power of
regulators over organisations such as ANSTO.[18]
3.33
ANSTO reaffirmed that communication and consultation is essential:
I believe we have a duty and a burden to continue to
communicate with stakeholders in the shire and in the broader region. But I do
not think there are any fundamental issues that would in any way compromise the
quality of the thinking and the planning that has underpinned this application.[19]
3.34
At the public hearing, ANSTO undertook to provide a further submission
addressing the concerns of the Sutherland Shire Council. This submission
acknowledges and responds to the Council’s concerns.[20]
Committee comment
3.35
The Committee appreciates ANSTO’s willingness to acknowledge the
concerns of the local community and to publicly respond to issues raised in the
submission from the Sutherland Shire Council.
3.36
In future, ANSTO should endeavour to provide more comprehensive detail
in its initial submissions wherever possible.
3.37
The Committee notes ANSTO’s ongoing engagement with the Council and expects
ANSTO to continue to engage with the Council and the local community, provide
timely public information wherever possible and address issues of concern as
they arise.
3.38
The Committee expects ANSTO to consult with the Council and other
interested stakeholders once the detailed designs are available.
3.39
The Committee accepts ANSTO’s undertakings that waste will not be stored
over the long-term at ANSTO’s Lucas Heights site. The Committee also accepts
ANSTO’s statement that the Synroc plant will not process nuclear waste from
other countries.
Costs
3.40
ANSTO acknowledged that it does not have a detailed design for either
the Mo-99 facility or the Synroc facility at this point in time. However, ANSTO
indicated that this is a standard ANSTO process and costs are estimated with
this in mind:
We have had this discussion with the committee in previous
meetings. The challenge is to have a sufficiently advanced design whereby you
can have a predictable set of costs but not so advanced that you consume public
resources to a great degree. So we are currently at the point where we have not
yet entered into a detailed design, because that is when you spend all of the
money on detailing all of the engineering issues. We have essentially completed
the preliminary design for the Synroc plant and we are ready to roll on the
detailed design. For the nuclear medicine plant, we are completing the
preliminary design during the course of this next part of the calendar year
[the detailed design will commence in around August-September].[21]
3.41
ANSTO provided significant detail in the public hearing regarding its
processes for developing cost estimates, including how it develops contingency
estimates:
… at the early stages of project development we will have an
envelope in which we are operating in which you will have as many defined costs
as you can define and a large contingency. As you move through the stage-gates
and you get more predictability and more certainty, the contingency tends to
shrink and the scope of the project gets better and better defined as you move
through it. The reason I am confident that ANSTO can operate within the budget that
we have secured for this project is that within our strategic assets projects
that we are currently delivering, which is a portfolio of about $300 million in
value, we are not experiencing cost blow-outs. For example, our own internal
construction team works up the work that we then provide to people like
quantity surveyors and others to assist us, and we are finding that we are very
close to the types of estimates that they will then confirm with their work.
Ultimately, these are found to be pretty respectable estimates when we tender
out for the work to be done in detail.[22]
3.42
ANSTO noted that the competitive nature of the construction sector also
assists in keeping costs down.[23]
3.43
Further, ANSTO stated that it has been particularly cautious with cost
estimates for the Synroc plant, given it is a first-of-its-kind development:
… we have drawn on the knowledge of international nuclear
engineering reviewers to come and review, in detail, the engineering status of
that project so that we can be assured, with their independent view, that we
have developed the capacity and the facilities to the level where they are
manufacturable, constructible and operable. That is a discipline that is seldom
used in first-of-a-kind projects, but we feel it is absolutely essential to
utilise that type of discipline.[24]
3.44
ANSTO indicated that it will repay all funds for both facilities once
they are operational. ANSTO also stated that it will also pay a dividend on the
production of nuclear medicine.[25]
Committee comment
3.45
The Committee acknowledges that ANSTO has a record of meeting project
budgets and avoiding cost blowouts.
3.46
The Committee is satisfied that ANSTO has adequate costing processes and
has incorporated adequate allowances for the proposed project.
Protection of intellectual property
3.47
The Committee raised some concerns about the protection of the
intellectual property surrounding Synroc. ANSTO stated emphatically:
I will make a very clear statement in the public setting: we
are very serious about protecting this. We think that this is a major future
engineering opportunity for Australia. We want to capture it for this country
and be able to go to other countries to do the work.[26]
3.48
ANSTO emphasised that there have been high-level bilateral discussions
with the United States regarding the sharing and protection of ANSTO’s intellectual
property in other instances.[27]
Committee comment
3.49
Following assurances during the in-camera hearing, the Committee is
satisfied that ANSTO is taking all appropriate measures to protect intellectual
property.
3.50
Further, the Committee encourages ANSTO to promote its various technologies
and capabilities, such as Synroc, to a wider audience.
Final Committee comment
3.51
The Committee’s briefing clearly highlighted the global need for an
increased supply of Mo-99, recent global shortages and the imminent closure of
the Canadian producer, which contributes a significant proportion of the global
supply of Mo-99.
3.52
The Committee’s inspection at Lucas Heights included the current Mo-99
facility and the OPAL reactor. The Committee met various ANSTO personnel during
the briefing and inspection and thanks them for their contributions to the
inquiry. The Committee also enjoyed lunch with some of ANSTO’s graduates, which
provided valuable insight into the work of the organisation.
3.53
The Committee appreciates the submission from the Sutherland Shire
Council. The Committee acknowledges ANSTO’s commitment to ongoing consultation
with the Council.
3.54
The Committee encourages ANSTO to promote and fully protect Australian
innovation and technology.
3.55
The Committee was satisfied with the evidence provided by ANSTO
regarding the proposed Nuclear Medicine Project. The Committee is satisfied
that the project has merit in terms of need, scope and cost.
3.56
Having regard to its role and responsibilities contained in the Public
Works Committee Act 1969, the Committee is of the view that this project
signifies value for money for the Commonwealth and constitutes a project which
is fit for purpose, having regard to the established need.
Recommendation 1 |
|
The Committee recommends that the House of Representatives
resolve, pursuant to Section 18(7) of the Public Works Committee Act 1969,
that it is expedient to carry out the following proposed work: The Australian
Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine Project. |